Abstract:(1) Background: The use of uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists results in neuroprotective benefits in patients with moderate to severe Alzheimer’s disease. In this study, we demonstrated mathematical and computer modelling of the excitotoxicity phenomenon and performed virtual memantine therapy. (2) Methods: A computer simulation environment of the N-methyl-D-aspartate receptor combining biological mechanisms of channel activation by means of excessive extracellular glutamic acid concentration in three models of excitotoxicity severity. The simulation model is based on sliding register tables, where each table is associated with corresponding synaptic inputs. Modelling of the increase in extracellular glutamate concentration, through over-stimulation of NMDA receptors and exacerbation of excitotoxicity, is performed by gradually increasing the parameters of phenomenological events by the power function. Pathological models were virtually treated with 3–30 μM doses of memantine compared to controls. (3) Results: The virtual therapy results of memantine at doses of 3–30 μM in the pathological models of excitotoxicity severity show statistically significant neuroprotective benefits in AD patients with moderate severity, 1.25 (95% CI, 1.18–1.32) vs. 1.76 (95% CI, 1.71–1.80) vs. 1.53 (95% CI, 1.48–1.59), (p < 0.001), to severe, 1.32 (95% CI, 1.12–1.53) vs. 1.77 (95% CI, 1.72–1.82) vs. 1.73 (95% CI, 1.68–1.79), (p < 0.001), in the area of effects on memory. A statistically significant benefit of memantine was demonstrated for all neuronal parameters in pathological models. In the mild severity model, a statistically significant increase in frequency was obtained relative to virtual memantine treatment with a dose of 3 μM, which was 23.5 Hz (95% CI, 15.5–28.4) vs. 38.8 Hz (95% CI, 34.0–43.6), (p < 0.0001). In the intermediate excitotoxicity severity model, a statistically significant increase in frequency was obtained relative to virtual memantine therapy with a 3 μM dose of 26.0 Hz (95% CI, 15.7–36.2) vs. 39.0 Hz (95% CI, 34.2–43.8) and a 10 μM dose of 26.0 Hz (95% CI, 15.7–36.2) vs. 30.9 Hz (95% CI, 26.4–35.4), (p < 0.0001). A statistically significant increase in frequency was obtained in the advanced excitotoxicity severity model as in the medium. (4) Conclusions: The NMDA antagonist memantine causes neuroprotective benefits in patients with moderate to severe AD. One of the most important benefits of memantine is the improvement of cognitive function and beneficial effects on memory. On the other hand, memantine provides only symptomatic and temporary support for AD patients. Memantine is prescribed in the US and Europe if a patient has moderate to severe AD. Memantine has also been approved for mild to moderate AD patients. However, its very modest effect provides motivation for further research into new drugs in AD. We are the first to present a mathematical model of the NMDA receptor that allows the simulation of excitotoxicity and virtual memantine therapy.

Antagonistic Effects of Memantine on Aβ25～35-induced Neurotoxicity

Protective effects of galantamine against Abeta-induced PC12 cell apoptosis by preventing mitochondrial dysfunction and endoplasmic reticulum stress.

Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil

Multifunctional Memantine Nitrate Significantly Protects Against Glutamate-Induced Excitotoxicity Via Inhibiting Calcium Influx and Attenuating PI3K/Akt/GSK3beta Pathway

Changes In Mitochondrial Dynamics During Amyloid Beta-Induced Pc12 Cell Apoptosis

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

The neuroprotective effect of memantine on methamphetamine-induced cognitive deficits

Memantine Improves Cognitive Function and Alters Hippocampal and Cortical Proteome in Triple Transgenic Mouse Model of Alzheimer's Disease

The Effect of Oxidative Stress and Memantine-Incorporated Reactive Oxygen Species-Sensitive Nanoparticles on the Expression of N-Methyl-d-aspartate Receptor Subunit 1 in Brain Cancer Cells for Alzheimer's Disease Application

Therapeutic efficacy of novel memantine nitrate MN‐08 in animal models of Alzheimer’s disease

The protective effects of memantine against inflammation and impairment of endothelial tube formation induced by oxygen-glucose deprivation/reperfusion

Therapeutic Effect of Memantine on Acute Tetramine Poisoning in Mice

<i>In Vitro</i> Effects of (+)MK-801 (dizocilpine) and Memantine on -Amyloid Peptides Linked to Alzheimer's Disease

The Computer Simulation of Therapy with the NMDA Antagonist in Excitotoxic Neurodegeneration in an Alzheimer’s Disease-like Pathology

A Promising Dual-functional Neuroprotective Derivative of Memantine

Proanthocyanidins Affects the Neurotoxicity of Aβ25-35 on C57/bl6 Mice.

Multicenter Research on Efficacy and Tolerance of Memantine in Chinese Patients with Alzheimer's Disease

Protective Effect of Memantine on N-methyl-D-aspartate Receptor in Dichlorvos-Poisoned Rat Brain

Memantine Ameliorates Tau Protein Deposition and Secondary Damage in the Ipsilateral Thalamus and Sensory Decline Following Focal Cortical Infarction in Rats

[Effects of Antagonist and Agonist of Nicotinic Acetylcholine Receptors on Injury of Rat Neurons Induced by Amyloid Β-Protein].

Effects of memantine hydrochloride on serum S100B protein and anti-brain anti-body levels in patients with Alzheimer disease